Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy

A PHASE 1, DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, TOLERABILITY, IMMUNOGENICITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF MULTIPLE ESCALATING DOSAGES OF RN6G (PF-04382923) IN SUBJECTS WITH ADVANCED DRY, AGE-RELATED MACULAR DEGENERATION (AMD) INCLUDING GEOGRAPHIC ATROPHY

The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.

Inclusion Criteria:

• Be of non-child bearing potential
• Diagnosis of dry AMD including uni- or multi-focal geographic atrophy without foveal involvement
• BCVA of 20/50 or better in the study eye

Exclusion Criteria:

• Evidence of ocular disease other than advanced AMD or GA in the study eye
• History or diagnosis of exudative (wet) AMD, with subretinal or choroidal neovascular lesions in the study eye
• Presence of disease or condition that might compromise the cardiovascular, hematological, renal, hepatic, pulmonary, endocrine, central nervous immune, or gastrointestinal system
• Requires ocular or systemic medications that are known to be toxic to the lens, retina or optic nerve